Sarah Premji, MD, of Sarah Cannon Research Institute, discusses community trial access, biomarker-driven drug development, and key breast cancer studies to watch.
|Videos|June 30, 2016
The Importance of Multi-Gene Panel Testing for BRCA Mutations
Author(s)Allison W. Kurian, MD, MSc
Allison W. Kurian, MD, MSc, associate professor of Medicine and of Health Research and Policy, Stanford University School of Medicine, discusses two ongoing trials utilizing multi-gene panels to uncover previously undetected risks in patients with breast and ovarian cancer.
Advertisement
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
Komal L. Jhaveri, MD, discusses the unmet need, EMBER-3 data, and future directions after the FDA approved imlunestrant plus abemaciclib for ESR1-mutated breast cancer.
Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
The FDA approved tucatinib with trastuzumab and pertuzumab as maintenance therapy in HER2-positive breast cancer, based on median PFS of 24.9 vs 16.3 months in HER2CLIMB-05.
Lyudmila Bazhenova, MD, explains why the updated taletrectinib label does not change her practice and reviews new WCLC subgroup data in ROS1+ NSCLC.
The ADC rinatabart sesutecan showed efficacy regardless of FRα status in heavily pretreated platinum-resistant ovarian cancer with a tolerable safety profile.
Ohio Medicaid patients with breast cancer often miss genomic tests; use stays under 40%, with stage, race, and long-term care status driving disparities.
Andrew T. Kuykendall, MD, explains the significance of the FDA approval of rusfertide for polycythemia vera.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Tucatinib Maintenance Regimen in HER2+ Metastatic Breast Cancer
2
Costa Explains What Drives Survival Benefit With Tec/Dara in Myeloma
3
c-Met ADC Temab-A Gains 2 FDA Breakthrough Designations in CRC, NSCLC
4
Phase 3 Trial of Daraxonrasib Plus Zoldonrasib Begins in RAS G12D PDAC
5